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ABSTRACT
Objectives: Intrauterine growth restriction (IUGR) is one of the main global causes of increased perinatal mortality and fetal 
and neonatal morbidity. It remains a key challenge for modern perinatal medicine. Negative effects of IUGR are manifested 
not only in the perinatal period but also at the later stages of life. Proinflammatory cytokines and their polymorphisms 
are hypothesized to play an important role in IUGR pathomechanisms. The aim of the study was to determine the role 
of selected polymorphisms (-238G > A, -308G > A and -376G > A) of tumor necrosis factor alpha (TNF-α) in the etiology of 
intrauterine growth restriction.
Material and methods: The study included 120 patients with IUGR (mean age 30.32, mean gestational age 36.34 gestational 
weeks) and 135 healthy pregnant women (mean age 31.63, average week of delivery 38.76). The investigated polymorphisms 
were determined by PCR/RFLP methods.
Results: Higher frequency of TNF-α mutated allele -308A was found in a subgroup of women whose pregnancy en-
ded < 37 weeks  (18.5 vs. 12.2% in control , OR = 1.63, p = 0.09) and in the subgroup of women with a score ≥ 3 UAS 
(20.6 vs. 12.2% in control , OR = 1.86, p = 0.06). Heterozygous genotype -308GA was associated with at least 3 times greater 
risk of three or four abnormalities in uterine arteries score (41.2 vs. 20.0 in control, OR = 2.80, p = 0.01).
Conclusions: The obtained results suggest that the -308G > A TNF-α gene variant may play a role in the etiology of IUGR 
in the Polish population, but further studies on larger groups are needed.
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INTRODUCTION
Intrauterine Growth Restriction (IUGR) despite the con-
stant development and improvment of diagnostic methods 
still remains one of the most important problems of con-
temporary perinatal medicine [1–4].
Probably fetal growth disorders are responsible for 
genetically determined insulin resistance associated with 
the presence of glucokinase gene mutations and also for 
the lack of insulin sensitivity in adulthood. This results in 
abnormal vascular development in the fetal period and 
may increase the risk of hypertension in the future life. 
In response to postnatal compensatory hyperinsulinemia, 
these “small” and “lean” children may preferentially increase 
the amount of visceral fat tissue, and the cytokines secreted 
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by it, i.e. tumor necrosis factor-α (TNF-α) or plasminogen 
activator inhibitor (PAI-1) which support the state of insulin 
resistance and increase prothrombotic activity [5]. 
The proper functioning of the cytokine mesh is a key 
process for the development of trophoblast and placenta. 
Functional dysregulation and changes in the local and 
systemic cytokine system are likely to be involved in many 
complications during pregnancy. The correct expression 
of TNF-α has a beneficial role in the development of early 
pregnancy, affecting the maturation and correct placental 
differentiation [6]. Currently, it is suggested that TNF-α is 
crucial for the processes taking place in the placenta, such 
as the initiation of an inflammatory response, induction of 
apoptosis, cell proliferation, differentiation and migration. 
Intrauterine growth restriction with placental insufficiency 
is most often diagnosed in late pregnancy and sometimes 
accompanied by significant pathological changes in the 
placenta. This complication is associated with the reduc-
tion of uterine-placental flow. Increased synthesis of TNF-α 
and other proinflammatory cytokines may be the cause of 
IUGR in response to increasing hypoxia. TNF-α inhibits the 
growth of trophoblast and its migration to the walls of the 
spiral arteries, disrupts the development of the placenta 
and  is toxic to vascular endothelial cells [7]. In addition, 
TNF-α interferes the anticoagulant system and may cause 
thrombosis in placental vessels [8]. Therefore, it can di-
rectly contribute to the development of IUGR by causing 
apoptosis of trophoblast cells, insufficient remodelling 
of spiral arteries, abnormal implantation and placental 
insufficiency [9]. 
The gene coding for TNF is located within the genes 
of mean histocompatibility complex class III (MHC III). In 
comparison to the other cytokine genes, the gene coding 
for TNF-α is relatively small (3 kb) and contains 3 introns and 
4 exons, of which the last exon encodes up to 80% of the final 
protein product [10]. The TNF gene is specifically located in 
the 6p21.33 segment on chromosome 6, between the HLA-B 
and HLA-DR tissue compatibility chip genes. The TNF-α 
promoter was cloned and sequenced in 1993 by Takashiba 
et al. It contains many polymorphic sites e.g. at positions: 
-1031, -863, -857, -419, -376, -308, -238, -163 [11].
Aim of the study
The aim of the study was to evaluate the significance of 
selected tumour necrosis factor-alpha (TNF-α) gene poly-
morphisms in the etiology of intrauterine growth restriction 
(IUGR). This goal was achieved by analyzing the frequen-
cy of genotypes and alleles of polymorphisms -238G > A, 
-308G > A and -376G > A of the TNF-α gene, estimation of 
Doppler flow in uterine arteries and correlation of the stu-
died polymorphisms with Doppler flows.
MATERIAL AND METHODS
Study and control group
The study was conducted in two groups of women: 
120 patients who were diagnosed with IUGR during pre-
gnancy (fetal weight < 2 SD or below the 10th percentile due 
to a given gestational age and gender) and in the control 
group of 135 pregnant women who did not have features 
of intrauterine growth restriction. Patients were qualified to 
the study and control group within the Department of Per-
inatology and Women’s Diseases at the Medical University of 
Karol Marcinkowski in Poznań from June 2012 to June 2014.
All patients were informed about the purpose and scope 
of the study and gave their written consent. The acceptance 
for performing research was obtained from Bioethics Com-
mittee of the Medical University of Karol Marcinkowski in 
Poznań (No. 145/12).
The mean age of patients in the study group was 
30.32 years, the average gestational age at delivery: 
36.34 weeks of pregnancy. The study group included: 
74 primaparas, and 46 multiparas. During the analysis of 
the results, the division of 120 women from the study group 
was carried out twice:
•	 due to the end of pregnancy
a) subgroup A — 46 women whose pregnancy end-
ed < 37 weeks
b) subgroup B — 74 women whose pregnancy end-
ed ≥ 37 weeks
•	 according to the uterine artery flow rate (UAS) scale
c) subgroup C — 86 women with < 3 UAS points
d) subgroup D — 34 women with ≥ 3 UAS points.
The point scale of uterine artery score (UAS) — point-
-by-point characterizes the nature of the flow:
•	 presence of notch in the right uterine artery 1 pt.
•	 presence of notch in the left uterine artery 1 pt.
•	 pulsation index PI > 1.2 in the right uterine artery 1 pt.
•	 pulsation index PI > 1.2 in the left uterine artery 1 pt.
In the control group, the average age of patients was 
31.63 years, and mean pregnancy duration was 38.76 we-
eks. The control group included: 51 primaparas and 84 mul-
tiparas.
All women qualified for in to the study, both IUGR and 
control groups were  Caucasians and of Polish nationality. 
All women from both groups were in single pregnancy. The 
gestational age was confirmed based on the date of the last 
menstrual period, including the regularity and duration of 
the monthly cycles, ultrasound examination carried out in 
the first trimester of pregnancy and the date of first fetal 
movements. In the second trimester of pregnancy, another 
ultrasound examination was performed in which the pre-
sence of fetal malformations was excluded. Clinical charac-
teristics of patients from both groups is presented in Table 1. 
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Each patient was evaluated for the value of Doppler 
flow in uterine arteries. Patients with multiple pregnancy, 
prenatally diagnosed congenital malformations, chromo-
somal aberrations and fetal genetic syndromes, gestational 
and pregestational diabetes, chronic hypertension, gesta-
tional hypertension and pre-eclampsia, threatening pre-
mature delivery, chorioamninitis and premature rupture 
of the membranes were excluded from the study. None of 
the patient was treated with acetylsalicylic acid and nitric 
oxide donors.
Ultrasound examination
In the course of the study, a thorough ultrasound exami-
nation was performed in all patients from the IUGR and con-
trol group of healthy pregnant women. In order to ensure 
repeatability of analyzes, all examinations were performed 
Table 1. Selected clinical data of patients from the IUGR and control group
Clinical date of the examined women IUGR(n = 120)
Control group
(n = 135) P
Age (years)
mean ± SD
min-max 
median
 
30.32 ± 4.89
17.00–41.00
31.00
 
31.63 ± 4.68
20.00–45.00
31.00
0.03
Height [cm]
mean ± SD
min-max 
median
 
166.84 ± 5.90
151.00–184.00
167.00
 
167.53 ± 5.67
155.00–180.00
168.00
0.35
Weight before pregnancy [kg]
mean ± SD
min-max 
median
 
60.68 ± 9.58
42.00–98.00
60.00
 
65.83 ± 12.21
45.00–116.00
64.00
0.0014
Weight at pregnancy ending [kg]
mean ± SD
min-max 
median
 
72.34 ± 11.88
47.00–125.00
73.00
 
78.21 ± 12.01
53.00–121.00
76.00
0.0003
BMI before pregnancy [kg]
mean ± SD
min-max 
median
 
21.77 ± 3.14
15.57–35.14
21.17
 
23.43 ± 3.96
17.87–36.68
22.60
0.0006
BMI at pregnancy ending [kg]
mean ± SD
min-max 
median
 
25.95 ± 3.91
17.30–44.82
25.58
 
27.86 ± 3.95
21.23–40.90
27.51
0.0001
ΔBMI
mean ± SD
min-max 
median
 
4.19 ± 1.79
0.00–9.68
4.10
 
4.43 ± 2.09
–1.73–10.29
4.20
0.32
BP syst. [mmHg]
mean ± SD
min-max 
median
 
114.83 ± 11.87
80.00–130.00
120.00
 
112.67 ± 12.09
80.00–130.00
110.00
0.15
BP diast. [mmHg]
mean ± SD
min-max 
median
 
72.38 ± 9.01
50.00–80.00
80.00
 
70.70 ± 8.48
50.00–80.00
70.00
0.13
primaparas
multiparas
74 (61.67%)
46 (38.33%)
51 (37.78%)
84 (62.22%) 0.0001
Delivery
vaginal delivery
cesarian section
operative vaginal delivery
(forceps, vacuum extractor)
 
33 (27.50%)
84 (70.00%)
3 (2.50%)
 
 
55 (40.74%)
78 (57.78%)
2 (1.48%)
 
0.08
Cigarette smoking
yes
no
 
6 (5.00%)
114 (95.00%)
 
5 (3.70%)
130 (96.30%)
0.61
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by one person and using the same General Electric Voluson 
730 Expert (GENERAL ELECTRIC Co, USA).
Ultrasound examinations of fetal biometry and Doppler 
flows in the right and left uterine arteries (RUA, LUA) were 
performed. The parameters used in the ultrasound devise 
were constant. The angle of incidence of ultrasound was ad-
justed to the vessel in which the Doppler flow was assessed 
and did not exceed 30º. During the Doppler examination, 
a dose of energy not exceeding 50 mW/cm² (lower than the 
limit values adopted by the American Institute of Medical 
Ultrasonography) was used. Each test was conducted in 
a semi-recumbent position on the left side to avoid the so-
-called lower vena cava syndrome caused by the pressure 
of the pregnant uterus. The exposure time for ultrasound 
did not exceed 15 minutes.
Genetic analysis
The genetic analysis examined the incidence of three 
promoter polymorphisms of the TNF-α gene: -238G > A, 
-308G > A, -376G > A. The analysis of genetic polymorphisms 
was performed by polymerase chain reaction (PCR) and 
restriction fragment length polymorphism (RFLP). Genetic 
analysis was carried out at the Laboratory of Molecular 
Biology at the Department of Perinatology and Women’s 
Diseases of the Medical University of Poznan.
Leukocyte DNA isolation was performed using a com-
mercial QIAamp DNA Blood Kit (QIAGEN Inc., Germany).
The isolated DNA was stored at minus 80°C. After isola-
tion, the obtained DNA was checked by spectrophotome-
tric measurement (BioPhotometer, Eppendorf, USA) and 
electrophoresis on 0.8% agarose gels, where the DNA was 
visible as a single band.
For amplification of the TNF-α gene fragment containing 
the -376G > A polymorphism, primers with the following se-
quences were used: 5’-AAg AAT CAT TCA ACC AgC gg-3’ and 
5’-CCT CAA Cgg ACT CAg CCT TC-3’ (TibMolBiol, Poland). The 
length of the PCR product was 393 bp. For the amplification 
of the segment containing -238G > A and -308G > A poly-
morphisms, the following primers were used: 5’-AAA Tgg 
Agg CAA Tag gTT TTg Agg ggC TTg-3’ and 5’-TAC CCC TCA 
CAC TCC CCA TCC TCC CTg ATC-3’ (TIBMolBiol Poland), which 
allowed to obtain a fragment of 131 bp. (underlined letter 
A means mismatch at the 3 ‘end of the primer to the sequ-
ence to introduce the restriction site for the BspPI restriction 
enzyme). All reactions were performed using the Dyad DNA 
Engine thermal cycler (BioRad, USA).
The PCR products were hydrolyzed with restriction en-
zymes: TasI (Tsp509I) for -376G > A, BspPI (AlwI) for -238G > A 
and FaqI (BsmFI) for -308G > A. All reactions were carried out 
according to the procedures recommended by the manu-
facturer. Genotype identification was performed by means 
of electrophoresis on 3% agarose gels in TBE buffer. The gels 
were stained with Midori Green DNA Stain (NIPPON Gene-
tics, Germany) and visualized under UV light. Depending 
on the genotype, the following fragments were obtained: 
-376G > A (GG — 393, GA — 393, 319, 74, AA — 319, 74 bp), 
-238 G > A (GG — 110, 21, GA — 131, 110, 21, AA — 131 bp), 
-308G > A (GG — 86, 45, GA — 131, 86, 45, AA 131 bp).
Statistical analysis
The statistical analysis of the obtained results was per-
formed using the SPSS 22.0 PL statistical program for Win-
dows. The distribution of continuous variables in terms of 
its compatibility with the normal distribution was asses-
sed using the Kolmogorov-Smirnov test with the Lilliefors 
amendment.
The results of genetic tests were statistically analyzed, 
the frequency of occurrence of genotypes and alleles be-
tween the test group and the control group was compared. 
A chi square test and one-sided Fisher exact test were used. 
The risk ratio (WR) was also calculated regarding the appro-
priate confidence intervals (95% CI). The p value < 0.05 was 
considered statistically significant. The observed values of 
the occurrence frequency of particular genotypes were 
compared with the expected values, which were determined 
based on the frequency of alleles according to the Hardy-
-Weinberg law.
The analysis of linkage disequilibrium for the studied 
polymorphisms of the TNF-α gene and the analysis of the 
incidence of haplotypes was carried out using the Haplo-
view version 4.2 program. The significance correction for 
multiple testing (1000 permutations) included in the pro-
gram was also used.
RESULTS
Analysis of the presence of TNF-α gene 
polymorphisms
-238G > A TNF-α gene polymorphism
As a result of TNF-α -238G > A polymorphism analysis, 
more frequent occurrences of -238GG non mutated homo-
zygotes were observed in the control group (91.9 vs. 88.3% 
in the group with hypotrophy, OR = 0.67, p = 0.23) and 
genotype -238GA was more frequent in the study group 
(11.7 vs. 8.1%, OR = 1.49, p = 0.23). The study did not report 
the presence of a homozygous mutated -238AA genotype 
among the studied women.
The incidence of alleles did not differ significantly be-
tween the groups: for the mutated -238A allele (5.8 vs. 4.1%, 
WR = 1.46, p = 0.23), and for the wild-type allele -238G 
(94.2 vs. 95.9%, WR = 0.69, p = 0.23). The distribution of geno-
types and alleles in both groups met the assumptions of the 
Hardy-Weinberg equilibrium (test group: chi square = 0.46, 
p = 0.50 and control group: chi square = 0.24, p = 0.62). The 
obtained results are presented in Table 2.
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 -308G > A TNF-α gene polymorphism
During the analysis of the frequency of genotypes and 
alleles of the -308G > A polymorphism, a higher turnout of 
homozygous genotype -308GG and homozygous mutated 
-308AA genotype in the control group of healthy women was 
recorded compared to the study group (77.8% vs. 69.2% and 
2.2% vs. 1.6% in the group with hypotrophy, p = 0.08 and 
p = 0.56). The opposite situation was observed in the case 
of the heterozygous -308GA genotype, which was more 
frequent in the group of women with IUGR (29.2% vs. 20.0% 
in the control group, p = 0.06).
When analyzing the incidence of alleles for this poly-
morphism, it was observed that the mutated allele -308A 
was more frequent in the study group (16.3% vs. 12.2%, 
OR = 1.39, p = 0.12), while in the control group the wild al-
lele -308G was more frequent (87.8% vs. 83.7% in the group 
with hypotrophy, OR = 0.72, p = 0.12) (Tab. 3). Both studied 
groups met the Hardy-Weinberg equilibrium assumptions 
(test group: chi square = 0.61, p = 0.43 and control group: 
chi square = 0.62, p = 0.43) (Tab. 2).
-376G > A TNF-α gene polymorphism
For TNF-α gene -376G > A polymorphism, none of the 
patients had a genotype containing both mutated -376AA al-
leles. In the group of women with fetal hypotrophy, the hete-
rozygous genotype -376GA was more frequent (2.5 vs. 0.7% 
in the control group, OR = 3.44, p = 0.27).
During the analysis, a higher incidence of the mutated 
-386A allele was also observed, which was 1.3% compared to 
the control group of 0.4% (OR = 3.41, p = 0.27). The analyzed 
groups of women met the assumptions of the Hardy-We-
inberg balance (test group: chi square = 0.01, p = 0.89 and 
control group: chi square = 0.002, p = 0.97). The obtained 
results are presented in Table 2.
Table 2. Incidence of genotypes and alleles of TNF-α gene polymorphisms in the group of women with IUGR and in the control group
TNF-α
IUGR
(n = 120)
Control group
(n = 135)
OR 95%PU p
Observed value
n (%)
Expected value
(%)
Observed value
n (%)
Expected value
(%)
-3
76
G 
> 
A
GG 117 (97.5) 97.5 134 (99.3) 99.3 0.29 0.03–2.84 0.27
GA 3 (2.5) 2.5 1 (0.7) 0.7 3.44 0.35–33.48 0.27
AA 0 (0.0) 0.0 0 (0.0) 0.0 — — —
Total 120 (100.0) 135 (100.0)
Alleles
G 237 (98.7) — 269 (99.6) — 0.29 0.03–2.84 0.27
A 3 (1.3) — 1 (0.4) — 3.41 0.35–32.96 0.27
Total 240 (100.0) 270 (100.0)
-3
08
G 
> 
A
GG 83 (69.2) 70.2 105 (77.8) 77.0 0.64 0.37–1.12 0.08
GA 35 (29.2) 27.2 27 (20.0) 21.5 1.65 0.93–2.93 0.06
AA 2 (1.6) 2.6 3 (2.2) 1.5 0.75 0.12–4.54 0.56
Total 120 (100.0) 135 (100.0)
Alleles
G 201 (83.7) — 237 (87.8) — 0.72 0.44–1.18 0.12
A 39 (16.3) — 33 (12.2) — 1.39 0.84–2.30 0.12
Total 240 (100.0) 270 (100.0)
-2
38
G 
> 
A
GG 106 (88.3) 88.7 124 (91.9) 92.0 0.67 0.29–1.54 0.23
GA 14 (11.7) 11.0 11 (8.1) 7.8 1.49 0.65–3.42 0.23
AA 0 (0.00) 0.3 0 (0.00) 0.2 — — —
Total 120 (100.0) 135 (100.0)
Alleles
G 226 (94.2) — 259 (95.9) — 0.69 0.31–1.54 0.23
A 14 (5.8) — 11 (4.1) — 1.46 0.65–3.28 0.23
Total 240 (100.0) 270 (100.0)
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Table 3. Incidence of genotypes and alleles of TNF-α gene polymorphisms in the subgroups separated due to the end of pregnancy and in 
the control group
TNF-α
Childbirth < 37 tc. (n = 46) Childbirth  ≥ 37 tc. (n = 74) Control group(n=135)
Observed 
value n (%)
Expected 
value (%) OR p
Observed 
value n (%)
Expected 
value (%) OR p
Observed 
value n (%)
Expected 
value (%)
-3
76
G 
> 
A
GG 46 (100.0) 100.0 — — 71 (95.9) 96.0 0.18 0.13 134 (99.3) 99.3
GA 0 (0.0) 0.0 — — 3 (4.1) 4.0 5.66 0.13 1 (0.7) 0.7
AA 0 (0.0) 0.0 — — 0 (0.0) 0.0 — — 0 (0.0) 0.0
Total 46 (100.0) 74 (100.0) 135 (100.0)
Alleles
G 92 (100.0) — — — 145 (98.0) — 0.18 0.13 269 (99.6) —
A 0 (0.0) — — — 3 (2.0) — 5.57 0.13 1 (0.4) —
Total 92 (100.0) 148 (100.0) 270 (100.0)
-3
08
G 
> 
A
GG 30 (65.2) 66.5 0.54 0.07 53 (71.6) 72.5 0.72 0.20 105 (77.8) 77.0
GA 15 (32.6) 30.1 1.94 0.06 20 (27.0) 25.3 1.48 0.16 27 (20.0) 21.5
AA 1 (2.2) 3.4 0.98 0.73 1 (1.4) 2.2 0.60 0.55 3 (2.2) 1.5
Total 46 (100.0) 100.0 74 (100.0) 100.0 135 (100.0)
Alleles
G 75 (81.5) — 0.61 0.09 126 (85.1) — 0.80 0.27 237 (87.8) —
A 17 (18.5) — 1.63 0.09 22 (14.9) — 1.25 0.27 33 (12.2) —
Total 92 (100.0) — 148 (100.0) — 270 (100.0)
-2
38
G 
> 
A
GG 41 (89.1) 89.4 0.73 0.38 65 (87.8) 88.2 0.64 0.24 124 (91.9) 92.0
GA 5 (10.9) 10.3 1.37 0.38 9 (12.2) 11.4 1.56 0.24 11 (8.1) 7.8
AA 0 (0.0) 0.3 — — 0 (0.0) 0.4 — — 0 (0.00) 0.2
Total 46 (100.0) 100.0 74 (100.0) 100.0 135 (100.0)
Alleles
G 87 (94.6) — 0.74 0.38 139 (93.9) — 0.66 0.24 259 (95.9) —
A 5 (5.4) — 1.35 0.38 9 (6.1) — 1.52 0.25 11 (4.1) —
Total 92 (100.0) — 148 (100.0) — 270 (100.0)
Analysis of the prevalence of genotypes  
and alleles of TNF-α polymorphisms depending 
on the week of pregnancy ending
Analysis of the frequency of occurrence of genotypes and 
alleles of the studied polymorphisms was performed after 
dividing the study group of women into two subgroups due 
to pregnancy ending  (subgroup A — ending of pregnan-
cy < 37 weeks, subgroup B — ending of pregnancy ≥ 37 weeks).
For the polymorphism -376G > A, there were no genoty-
pes containing the mutated -376A allele in the A subgroup of 
women giving birth before 37 weeks, while in the subgroup 
of giving birth after 37 weeks three patients were carriers 
of the heterozygous -376GA genotype (4.1% vs. 0.7% in the 
control group, OR = 5.66, p = 0.13). The mutated -376A allele 
occurred in 2.0% of women giving birth after 37 weeks and 
in 0.4% in the control group, this difference was not statisti-
cally significant (p = 0.13).
For polymorphism -308G >  A, the most interesting observa-
tion was higher frequency of heterozygous genotype -308GA 
in the group where the birth took place < 37 weeks (32.6% 
vs. 20.0%, OR = 1.94, p = 0.06). There was also a higher inciden-
ce of the -308A mutated allele in this subgroup (18.5 vs. 12.2%). 
Similar results were obtained by examining the distribution of 
alleles and genotypes for this polymorphism in the B subgroup 
of women giving birth after 37 weeks. The 306GA heterozy-
gous genotype was observed more frequently compared to 
the control group (27.0 vs. 20.0%). The genotype containing 
both mutated -308AA alleles occurred more frequently in 
the control group (2.2 vs. 1.4% in the subgroup > 37 weeks). 
The incidence of the -308A mutated allele was higher in the 
subgroup > 37 weeks (14.9 vs. 12.2%, OR = 1.25, p = 0.27).
For polymorphism -238G > A of the TNF-α gene in the 
group of women who delivered children with hypotro-
phy < 37 weeks a lower incidence of -238GG genotype was ob-
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served (89.1 vs. 91.9% in the control group, OR = 0.73, p = 0.38) 
and a higher incidence of the heterozygous -238GA genotype 
containing one mutated allele (10.9 vs. 8.1% in the control 
group, OR = 1.37, p = 0.38). Similar observations were made for 
the frequency of alleles of this polymorphism. The -238G allele 
was less frequent in the subgroup < 37 weeks (94.6 vs. 95.9%, 
OR = 0.74), while the -238A mutated allele appeared more 
frequently in the examined subgroup (5.4 vs. 4.1%, OR = 1.35, 
p = 0.38). In the subgroup giving birth after 37 weeks the 
mutated -238A allele was even more frequent (6.1 vs. 4.1% in 
the OR control group = 1.52, p = 0.25), and the wild type -238G 
allele occurred in this subgroup in 93.9% of women (Tab. 3).
Analysis of the prevalence of genotypes  
and alleles of TNF-α polymorphisms depending 
on the UAS score
In the next stage of the research, the study group was 
divided into two subgroups taking into account the point 
scale of uterine artery flow (UAS) (subgroup C — 86 women 
with < 3 points, subgroup D — 34 women with ≥ 3 points)
In terms of TNF-α gene polymorphism, -376GA hetero-
zygous genotype was more frequent in patients who scored 
less than three points in the UAS scale (3.5% vs. 0.7% in the 
control group, OR = 0.21 p = 0.16). In a subgroup of 34 wo-
men who scored three or more points, only a homozygous 
unmuted genome was found -376GG.
Interesting results were obtained during the analysis of 
the -308G > A polymorphism of the TNF-α gene. Among wo-
men from subgroup D: with three or more points of the UAS 
scale, the heterozygous genotype -308GA occurred more 
than twice as often as in the control group (41.2% vs. 20.0%, 
OR = 2.80, p = 0.01). In this subgroup, there was no single 
patient with a genotype containing both mutated alleles. Ge-
notype -308AA occurred in subgroup C in two patients (2.3%) 
and in the control group in three (2.2%). When analyzing the 
distribution of alleles in these subgroups and in the control 
Table 4. Incidence of genotypes and alleles of TNF-α gene polymorphisms in the subgroups separated due to the UAS score and in the 
control group
TNF-α
< 3 points UAS (n = 86) ≥ 3 points UAS (n = 34) Control group(n = 135)
Observed 
value n (%)
Expected 
value (%) OR p
Observed 
value n (%)
Expected 
value (%) OR p
Observed 
value n (%)
Expected 
value (%)
-3
76
G 
> 
A
GG 83 (96.5) 96.54 0.21 0.16 34 (100.0) 100.0 — — 134 (99.3) 99.3
GA 3 (3.5) 3.43 4.84 0.16 0 (0.0) 0.0 — — 1 (0.7) 0.7
AA 0 (0.0) 0.03 — — 0 (0.0) 0.0 — — 0 (0.0) 0.0
Total 86 (100.0) 100.0 34 (100.0) 135 (100.0)
Alleles
G 169 (98.3) — 0.21 0.17 68 (100.0) — — — 269 (99.6)
A 3 (1.7) — 4.78 0.17 0 (0.0) — — — 1 (0.4)
Total 172 (100.0) — 68 (100.0) — 270 (100.0)
-3
08
G 
> 
A
GG 63 (73.3) 62.8 0.78 0.27 20 (58.8) 63.1 0.41 0.02 105 (77.8) 77.0
GA 21 (24.4) 21.4 1.29 0.27 14 (41.2) 32.7 2.80 0.01 27 (20.0) 21.5
AA 2 (2.3) 1.8 1.05 0.64 0 (0.0) 4.2 — — 3 (2.2) 1.5
Total 86 (100.0) 34 (100.0) 135 (100.0)
Alleles
G 147 (85.5) — 0.81 0.29 54 (79.4) — 0.54 0.06 237 (87.8) —
A  25 (14.5) — 1.22 0.29 14 (20.6) — 1.86 0.06 33 (12.2) —
Total 172 (100.0) — 68 (100.0) — 270 (100.0)
-2
38
G 
> 
A
GG 75 (87.2) 87.6 0.60 0.18 31 (91.2) 91.4 0.92 0.56 124 (91.9) 92.0
GA 11 (12.8) 12.0 1.65 0.18 3 (8.8) 8.4 1.09 0.56 11 (8.1) 7.8
AA 0 (0.0) 0.4 — — 0 (0.0) 0.2 — — 0 (0.00) 0.2
Total 86 (100.0) 34 (100.0) 135 (100.0)
Alleles
G 161 (93.6) 0.62 0.19 65 (95.6) 0.92 0.56 259 (95.9) —
A 11 (6.4) 1.61 0.19 3 (4.4) 1.09 0.56 11 (4.1) —
Total 172 (100.0) 68 (100.0) 270 (100.0)
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group, the occurrence of the -308G allele was the most fre-
quent in the control group — 87.8%, in 85.5% of women 
who obtained more than three points in the UAS scale and 
in 79.4% of patients with three and more points. The -308A 
mutated allele was most frequently observed in subgroup 
D (20.6% vs. 12.2% in the control group, OR = 0.54, p = 0.06).
In the case of TNF-α -238G > A polymorphism analysis, 
the most frequent occurrence of the genotype containing 
the -238A mutant allele was in the subgroup of women 
who scored less than three points (12.8% vs. 8.1% in the 
control group, OR = 0.60, p = 0.18). The incidence of geno-
types and alleles of this variant in the subgroup of women 
with less than three UAS points was comparable to the 
frequency of the control group: -238GG — 91.2 vs. 91.9%, 
-238GA — 8.8 vs. 8.1, G allele 95.6 vs. 95.9% and the -238A 
allele 4.4 vs. 4.1% (Tab. 4).
DISCUSSION
The number of reports in the world literature analyzing 
the incidence of cytokine polymorphisms in pregnant women 
diagnosed with IUGR is low. Hence, the studies carried out in 
the above work in the group of women with IUGR without any 
other accompanying complications are very interesting, both 
in terms of the collected group and the obtained  results. In 
the analyzed group of women, no direct significance of any of 
the studied polymorphisms (-238G > A, -308G > A, -376G > A) 
of the TNF-α gene in the etiology of IUGR was indicated. The 
results indicate that the -308G > A  polymorphism of TNF-α 
gene was more frequent in the subgroup of women who had 
a birth < 37 gw. (p = 0.06) and in the subgroup of women 
with ≥ 3 points. UAS (scale of flow through the uterine arteries) 
(p = 0.01) (for the allele -308A p = 0.06). In the other papers, the 
Authors also indicate the importance of the -308G > A TNF-α 
variant in the development of hypotrophy [12–15].
An attempt to explain the contribution of placental cyto-
kine gene polymorphisms in the mechanism of IUGR forma-
tion was made by researchers from Sweden. They analyzed 
gene expression and selected polymorphisms in 44 new-
borns with IUGR and 55 with normal body mass from the 
Pakistani population, where IUGR is more common than in 
Sweden. There were no statistically significant differences 
in mRNA expression for the TNF-α gene and the incidence 
of -308G > A polymorphism between the neonatal groups 
and their mothers. When comparing the incidence of this 
polymorphism in Pakistani women with Swedish Caucasians, 
a statistically significant difference was found (p < 0.04) [13].
In addition, in the present study, genetic coexistence 
was analyzed to assess the significance of genetic variants 
of TNF-α gene polymorphisms. An interesting observation 
of a higher frequency of occurrence of the -308GA / -376GG 
genotype combination in the subgroup in which the pre-
gnancy ended < 37 weeks (32.61 vs. 19.26%, OR = 2.03, 
p = 0.05) and in the subgroup of women with ≥ 3 points. UAS 
(41.18 vs. 19.26%, OR = 2.93, p = 0.01). In the subgroup of 
women with ≥ 3 points UAS also noted a higher frequ-
ency of the combination of -238GG / -308GA genotypes 
(41.18 vs. 18.52, OR = 3.08, p = 0.01). These observations 
indicate possible common interaction of genotypes and 
alleles of several TNF-α gene polymorphisms at the severity 
of IUGR-related complications.
In the work of Laddha et al. (2012) five promoter po-
lymorphisms of the TNF-α gene were studied [-238G > A 
(rs361525), -308G > A (rs1800629), -857C > T (rs1799724), 
-863C > A (rs1800630) and -1031T >C (rs1799964)] in a group 
of 977 Indian patients with vitiligo and 990 healthy con-
trols. Analysis of linkage disequilibrium showed a weak 
or moderate LD relationship between these five TNF-α va-
riants. The two polymorphisms studied also in the presen-
ted dissertation (-238G > A and -308G > A) in the article of 
Indian researchers occurred in moderate LD (D ‘= 0.485) [16]. 
Palmirotta et al. (2010) investigated the relationship betwe-
en serum TNF-α serum concentration and TNF-α gene pro-
motor polymorphisms (-376G > A, -308G > A and -238G > A) in 
the group of 200 Italian Caucasian women. The study group 
consisted of 100 patients (mean age 37 ± 5 years, range 
25–47) who had unexplained recurrent spontaneous abor-
tions (n = 31) or idiopathic infertility (n = 69). 100 healthy 
fertile women from the same geographical area (mean age 
38 ± 5 years, range 23–48) were qualified to the control gro-
up. In this work, the analysis of the coupling disequilibrium 
determined by the D ‘coefficient did not show any coupling 
disequilibrium between all three promoter variants. Genetic 
analysis showed a more frequent occurrence of the -238G 
allele (p = 0.028) and haplotype 3-loci (-376G / -308A / -238G) 
in the control group compared to women with pregnancy 
failure (p = 0.020). In this study, serum TNF-α protein was 
higher in the study group (1.5 [0.1–11.4] vs. 0.1 [0.1–3.8] 
pg/mL, p = 0.001), and multivariate regression analysis in-
dicated that the previously mentioned haplotype (-376G / A, 
-308G / A and -238G / A) is an independent factor associa-
ted with a lower level of TNF-α protein (p = 0.021) and the 
occurrence of abortions (p = 0.023). The authors suggest 
the association of TNF-α polymorphisms with recurrent 
miscarriages, particularly the -238GG variant and haplotype 
(-376G / -308A / -238G) as protective factors for recurrent 
pregnancy loss [17].
In the above work, exactly the same three promoter po-
lymorphisms were analyzed, in a numerically similar group 
of Polish, Caucasian patients and similarly, the analysis of lin-
kage disequilibrium did not show LD between the variants 
discussed. Haplotype (-376G / -308A / -238G) described in 
Palmirott et al. as a protective factor for the occurrence of 
pregnancy failure in the presented study was more frequent 
in the IUGR group compared to the control group (0.157% 
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vs. 0.119%), but no statistically significant difference was 
observed (p = 0.21) [16, 17].
CONCLUSIONS
1. More frequent occurrence of TNF-α mutated allele 
-308A in a subgroup of women whose pregnancy end-
ed < 37 weeks suggests the possible significance of this 
variant in the etiology of IUGR.
2. The statistically significant advantage of the TNF-α 
mutated -308A allele in the group of women with 
a score ≥ 3 UAS may indicate the significance of this 
variant in IUGR prediction.
3. The presence of the TNF-α heterozygous -308GA geno-
type is associated with a nearly 3-fold increase in the 
risk of three or four abnormalities in the point scale 
of uterine artery flow (UAS) and may be used in the 
prediction of IUGR.
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